JP2021513965A5 - - Google Patents
Info
- Publication number
- JP2021513965A5 JP2021513965A5 JP2020543314A JP2020543314A JP2021513965A5 JP 2021513965 A5 JP2021513965 A5 JP 2021513965A5 JP 2020543314 A JP2020543314 A JP 2020543314A JP 2020543314 A JP2020543314 A JP 2020543314A JP 2021513965 A5 JP2021513965 A5 JP 2021513965A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- composition according
- compound
- approximately
- disease
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023177591A JP2023171662A (ja) | 2018-02-16 | 2023-10-13 | アゾロピリミジン化合物による投薬 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862710394P | 2018-02-16 | 2018-02-16 | |
| US62/710,394 | 2018-02-16 | ||
| PCT/US2019/018009 WO2019161054A1 (en) | 2018-02-16 | 2019-02-14 | Dosing with an azolopyrimidine compound |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023177591A Division JP2023171662A (ja) | 2018-02-16 | 2023-10-13 | アゾロピリミジン化合物による投薬 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021513965A JP2021513965A (ja) | 2021-06-03 |
| JP2021513965A5 true JP2021513965A5 (https=) | 2022-02-21 |
| JP7417527B2 JP7417527B2 (ja) | 2024-01-18 |
Family
ID=67619607
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020543314A Active JP7417527B2 (ja) | 2018-02-16 | 2019-02-14 | アゾロピリミジン化合物による投薬 |
| JP2023177591A Pending JP2023171662A (ja) | 2018-02-16 | 2023-10-13 | アゾロピリミジン化合物による投薬 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023177591A Pending JP2023171662A (ja) | 2018-02-16 | 2023-10-13 | アゾロピリミジン化合物による投薬 |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US11478479B2 (https=) |
| EP (1) | EP3755333A4 (https=) |
| JP (2) | JP7417527B2 (https=) |
| KR (1) | KR102823186B1 (https=) |
| CN (1) | CN111818923A (https=) |
| AU (1) | AU2019222747B2 (https=) |
| CA (1) | CA3090922A1 (https=) |
| TW (1) | TWI879727B (https=) |
| WO (1) | WO2019161054A1 (https=) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3090922A1 (en) | 2018-02-16 | 2019-08-22 | Arcus Biosciences, Inc. | Dosing with an azolopyrimidine compound |
| EP3823614A4 (en) | 2018-07-18 | 2022-03-30 | Arcus Biosciences, Inc. | SOLID FORMS OF AN AZOLOPYRIMIDINE COMPOUND |
| CN113795267A (zh) | 2019-03-12 | 2021-12-14 | 艾库斯生物科学有限公司 | 致癌基因驱动的癌症的治疗 |
| WO2020205527A1 (en) | 2019-03-29 | 2020-10-08 | Arcus Biosciences, Inc. | Treatment of cancer utilizing an identified adenosine fingerprint |
| CN113121502A (zh) * | 2019-12-31 | 2021-07-16 | 山东铂源生物医药有限公司 | 一种杂芳烃类化合物、中间体、组合物及应用 |
| KR102646627B1 (ko) * | 2021-03-24 | 2024-03-13 | 주식회사 스탠다임 | 아데노신 a2a 수용체 및 아데노신 a2b 수용체의 이중 길항제, 및 이의 용도 |
| WO2024097736A1 (en) * | 2022-11-02 | 2024-05-10 | Arcus Biosciences, Inc. | Processes for preparing azolopyrimidine compounds |
Family Cites Families (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI330183B (https=) | 2001-10-22 | 2010-09-11 | Eisai R&D Man Co Ltd | |
| CA2551944A1 (en) | 2003-12-15 | 2005-06-30 | Almirall Prodesfarma Ag | 2, 6 bisheteroaryl-4-aminopyrimidines as adenosine receptor antagonists |
| TWI380996B (zh) | 2004-09-17 | 2013-01-01 | Hoffmann La Roche | 抗ｏｘ４０ｌ抗體 |
| PT2343320T (pt) | 2005-03-25 | 2018-01-23 | Gitr Inc | Anticorpos anti-gitr e as suas utilizações |
| PT1907424E (pt) | 2005-07-01 | 2015-10-09 | Squibb & Sons Llc | Anticorpos monoclonais humanos para o ligando 1 de morte programada (pd-l1) |
| EP1987839A1 (en) | 2007-04-30 | 2008-11-05 | I.N.S.E.R.M. Institut National de la Sante et de la Recherche Medicale | Cytotoxic anti-LAG-3 monoclonal antibody and its use in the treatment or prevention of organ transplant rejection and autoimmune disease |
| US8591886B2 (en) | 2007-07-12 | 2013-11-26 | Gitr, Inc. | Combination therapies employing GITR binding molecules |
| EP2044949A1 (en) | 2007-10-05 | 2009-04-08 | Immutep | Use of recombinant lag-3 or the derivatives thereof for eliciting monocyte immune response |
| AR072999A1 (es) | 2008-08-11 | 2010-10-06 | Medarex Inc | Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos |
| EP3255060A1 (en) | 2008-12-09 | 2017-12-13 | F. Hoffmann-La Roche AG | Anti-pd-l1 antibodies and their use to enhance t-cell function |
| KR101790802B1 (ko) | 2009-09-03 | 2017-10-27 | 머크 샤프 앤드 돔 코포레이션 | 항-ｇｉｔｒ 항체 |
| ES2722300T3 (es) | 2009-12-10 | 2019-08-09 | Hoffmann La Roche | Anticuerpos que se unen preferentemente al dominio extracelular 4 de CSF1R y su uso |
| US9169323B2 (en) | 2010-03-05 | 2015-10-27 | Hoffmann-La Roche Inc. | Antibodies against human CSF-1R |
| JP5989547B2 (ja) | 2010-03-05 | 2016-09-07 | エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト | ヒトｃｓｆ−１ｒに対する抗体及びその使用 |
| ES2365960B1 (es) * | 2010-03-31 | 2012-06-04 | Palobiofarma, S.L | Nuevos antagonistas de los receptores de adenosina. |
| HRP20190047T1 (hr) | 2010-05-04 | 2019-02-22 | Five Prime Therapeutics, Inc. | Protutijela koja se vežu na csf1r |
| MX337040B (es) | 2010-09-09 | 2016-02-09 | Pfizer | Moleculas de union a 4-1bb. |
| DE102011008352A1 (de) | 2011-01-12 | 2012-07-12 | Merck Patent Gmbh | 5-([1,2,3]Triazol-4-yl)-7H-pyrrolo-[2,3-d]pyrimidinderivate |
| JP6072771B2 (ja) | 2011-04-20 | 2017-02-01 | メディミューン，エルエルシー | Ｂ７−ｈ１およびｐｄ−１に結合する抗体およびその他の分子 |
| KR101764096B1 (ko) | 2011-11-28 | 2017-08-02 | 메르크 파텐트 게엠베하 | 항-ｐｄ-ｌ1 항체 및 그의 용도 |
| RU2658603C2 (ru) | 2011-12-15 | 2018-06-21 | Ф.Хоффманн-Ля Рош Аг | Антитела против человеческого csf-1r и их применения |
| KR20140127855A (ko) | 2012-02-06 | 2014-11-04 | 제넨테크, 인크. | Csf1r 억제제를 사용하는 조성물 및 방법 |
| AR090263A1 (es) | 2012-03-08 | 2014-10-29 | Hoffmann La Roche | Terapia combinada de anticuerpos contra el csf-1r humano y las utilizaciones de la misma |
| RU2670743C9 (ru) | 2012-05-11 | 2018-12-19 | Файв Прайм Терапьютикс, Инк. | Способы лечения состояний антителами, которые связывают рецептор колониестимулирующего фактора 1 (csf1r) |
| UY34887A (es) | 2012-07-02 | 2013-12-31 | Bristol Myers Squibb Company Una Corporacion Del Estado De Delaware | Optimización de anticuerpos que se fijan al gen de activación de linfocitos 3 (lag-3) y sus usos |
| CN107759690A (zh) | 2012-08-31 | 2018-03-06 | 戊瑞治疗有限公司 | 用结合群落刺激因子1受体(csf1r)的抗体治疗病状的方法 |
| BR112017021386A2 (pt) * | 2015-04-08 | 2018-07-03 | Lewis And Clark Pharmaceuticals, Inc. | carbamatos de alquinila com xantina substituída/carbamatos reversos como antagonistas de a2b. |
| MX373318B (es) * | 2015-08-11 | 2020-05-21 | Novartis Ag | 5-bromo-2,6-di-(1h-pirazol-1-il) pirimidin-4-amina-para su uso en el tratamiento del cáncer. |
| HUE064141T2 (hu) * | 2017-01-20 | 2024-02-28 | Arcus Biosciences Inc | Azolopirimidin rákkal összefüggõ rendellenességek kezelésére |
| US20200055883A1 (en) | 2017-02-17 | 2020-02-20 | Eisai R&D Management Co., Ltd. | Cyclic di-nucleotides derivative for the treatment of cancer |
| EP3601259B1 (en) | 2017-03-30 | 2022-02-23 | F. Hoffmann-La Roche AG | Isoquinolines as inhibitors of hpk1 |
| JP6453507B2 (ja) | 2017-03-30 | 2019-01-16 | アムジエン・インコーポレーテツド | Ｍｃｌ−１タンパク質を阻害する化合物 |
| AR111307A1 (es) | 2017-03-30 | 2019-06-26 | Takeda Pharmaceuticals Co | Derivados de 1,2-dihidroespiro[ciclohexan-1,3-indol] o 1,2-dihidroespiro[ciclohexan-1,3-pirrolo[3,2-b]piridina] como inhibidores de hexakisfosfato quinasa |
| EP3642240A1 (en) * | 2017-06-22 | 2020-04-29 | Novartis AG | Antibody molecules to cd73 and uses thereof |
| CA3090922A1 (en) | 2018-02-16 | 2019-08-22 | Arcus Biosciences, Inc. | Dosing with an azolopyrimidine compound |
-
2019
- 2019-02-14 CA CA3090922A patent/CA3090922A1/en active Pending
- 2019-02-14 CN CN201980013867.1A patent/CN111818923A/zh active Pending
- 2019-02-14 WO PCT/US2019/018009 patent/WO2019161054A1/en not_active Ceased
- 2019-02-14 KR KR1020207026519A patent/KR102823186B1/ko active Active
- 2019-02-14 JP JP2020543314A patent/JP7417527B2/ja active Active
- 2019-02-14 EP EP19754719.3A patent/EP3755333A4/en active Pending
- 2019-02-14 US US16/970,054 patent/US11478479B2/en active Active
- 2019-02-14 AU AU2019222747A patent/AU2019222747B2/en active Active
- 2019-02-15 TW TW108105187A patent/TWI879727B/zh active
-
2023
- 2023-03-23 US US18/188,780 patent/US20230338377A1/en not_active Abandoned
- 2023-10-13 JP JP2023177591A patent/JP2023171662A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021513965A5 (https=) | ||
| JP2022535120A5 (https=) | ||
| JP2021531314A5 (https=) | ||
| JP2019516711A5 (https=) | ||
| JP2020514311A5 (https=) | ||
| KR20170084034A (ko) | 암 치료용 의약 조성물 제조에서의 아젤니디핀의 용도 | |
| TWI641374B (zh) | 含低用量伊立替康鹽酸鹽水合物之抗腫瘤劑 | |
| JP2017505321A5 (https=) | ||
| JP6855488B2 (ja) | 食道癌を治療するためのキノリン誘導体の使用とその治療方法、医薬組成物及びキット | |
| JP2010523634A (ja) | Ａｚｄ２１７１およびａｚｄ６２４４またはｍｅｋ阻害剤ｉｉを含む併用療法 | |
| JP2014530181A5 (https=) | ||
| Nourbakhsh et al. | Biological and pharmacological activities of noscapine: Focusing on its receptors and mechanisms | |
| JP2024502446A5 (https=) | ||
| JP2017516827A5 (https=) | ||
| JP2021113228A (ja) | 重度腎機能障害を有する癌患者に対する治療方法 | |
| TWI869511B (zh) | 治療癌症之方法 | |
| JP2021511344A5 (https=) | ||
| US20130296356A1 (en) | Combinations | |
| JP2016502540A5 (https=) | ||
| JP2024538719A5 (https=) | ||
| CN110522753A (zh) | 一种新型抗肿瘤药物组合物、制剂和应用 | |
| JP2018511642A5 (https=) | ||
| JP2020521786A5 (https=) | ||
| TW202114682A (zh) | Mcl-1抑制劑與乳癌標準療法之組合，其用途及醫藥組合物 | |
| JP2023514426A5 (https=) |